Pérez-Flores EMI, Romero-Valenzuela I

Language: Spanish
References: 10
Page: 109-113
PDF size: 1189.92 Kb.

ABSTRACT

Introduction: ethylmalonic encephalopathy (EE) is a rare autosomal recessive metabolic disorder caused by mitochondrial dysfunction and accumulation of hydrogen sulfide and toxic metabolites. Clinical features include global developmental delay, seizures, hypotonia, and multisystem involvement that may mimic cerebral palsy, leading to delayed diagnosis. Objective: to present a clinical case of EE, emphasizing diagnostic challenges, therapeutic strategies, and the critical role of multidisciplinary rehabilitation. Case report: a 25-year-old male was initially diagnosed with spastic cerebral palsy and moderate intellectual disability. He exhibited chronic diarrhea, petechiae, acrocyanosis, spasticity, intestinal polyposis, and neurogenic bladder. After multiple evaluations, EE was confirmed at age 22 by genetic sequencing (ETHE1 c.488G›A, homozygous). Although specific pharmacological therapy began late, the patient achieved the longest survival ever reported, primarily due to long-term family support and an intensive pediatric rehabilitation program spanning nearly two decades. Results: published literature reports a maximum survival of approximately 11 years in most EE cases. This report documents the oldest patient with EE, highlighting the decisive impact of rehabilitation and sustained supportive care. Conclusions: EE should be considered in the differential diagnosis of atypical cerebral palsy, particularly when chronic diarrhea, acrocyanosis, or hemorrhagic manifestations are present. This case emphasizes the essential role of multidisciplinary rehabilitation and chronic care in improving quality of life and extending survival in individuals with disability due to rare metabolic disorders.

REFERENCES

1. Kashima DT, Sloan-Heggen CM, Gottlieb-SmithRJ, Barone Pritchard A. An atypically mild case ofethylmalonic encephalopathy with pathogenic ETHE1variant. Am J Med Genet A. 2023; 191 (6): 1614-1618.

2. Burlina AB, Dionisi-Vici C, Bennett MJ, Gibson KM,Servidei S, Bertini E et al. A new syndrome withethylmalonic aciduria and normal fatty acid oxidation infibroblasts. J Pediatr. 1994; 124 (1): 79-86.

3. Grosso S, Mostardini R, Farnetani MA, MolinelliM, Berardi R, Dionisi-Vici C et al. Ethylmalonicencephalopathy: further clinical and neuroradiologicalcharacterization. J Neurol. 2002; 249 (10): 1446-1450.

4. Pigeon N, Campeau PM, Cyr D, Lemieux B, Clarke JT.Clinical heterogeneity in ethylmalonic encephalopathy.J Child Neurol. 2009; 24 (8): 991-996.

5. Ersoy M, Tiranti V, Zeviani M. Ethylmalonicencephalopathy: Clinical course and therapy response inan uncommon mild case with a severe ETHE1 mutation.Mol Genet Metab Rep. 2020; 25: 100641.

6. Dionisi-Vici C, Diodato D, Torre G, Picca S, ParianteR, Picardo SG et al. Liver transplant in ethylmalonicencephalopathy: a new treatment for an otherwise fataldisease. Brain. 2016; 139 (Pt 4): 1045-1051.

7. Tam A, AlDhaheri NS, Mysore K, Tessier ME, Goss J,Fernandez LA et al. Improved clinical outcome following livertransplant in patients with ethylmalonic encephalopathy. AmJ Med Genet A. 2019; 179 (6): 1015-1019.

8. Lim J, Shayota BJ, Lay E, Elsea SH, Bekheirnia MR,Tessier MEM, et al. Acute strokelike presentation andlong-term evolution of diffusion restriction pattern inethylmalonic encephalopathy. J Child Neurol. 2021; 36(10): 841-852.

9. Bijarnia-Mahay S, Gupta D, Shigematsu Y, YamaguchiS, Saxena R, Verma IC. Ethylmalonic encephalopathy inan Indian boy. Indian Pediatr. 2016; 53 (10): 914-9116.

10. Satapathy AK, Correa A, Kabra M, Eichler S, RolfsA, Jana M, et al. Ethylmalonic encephalopathymasquerading as malabsorption syndrome: a casereport. Meta Gene. 2017; 13: 115-118.